Info graphic highlights the key steps for investors to watch in the drug development process. Continue reading
Category Archives: AZBio News
US OMB Proposes Updating Grant Guidance for Federal Programs
The US Office of Management and Budget has proposed streamlining its grant guidance and making other changes aimed at increasing the effectiveness and efficiency of federal programs. Continue reading
Sanofi expands global leadership team
Sanofi appoints two new Members to the Executive Committee to lead the new Commercial OrganizationContinue reading
Emergency Medical Services Study Awarded Society for Clinical Trials 2012 Trial of the Year
The Society for Clinical Trials has awarded the 2012 Trial of the Year to the Rapid Anticonvulsant Medication Prior to Arrival Trial, known as RAMPART, which has led to better pre-hospital treatment for people suffering prolonged seizures.Continue reading
It’s a wrap. Take aways from BIO2013
BIO2013, the 20th BIO International Convention, is one for the history books now. Let’s take a look at what was the talk of the town in Chicago.Continue reading
SynCardia Certified Centers Perform Record Number of Total Artificial Heart Implants During Q1 2013
World’s Only Approved Total Artificial Heart Surpasses 500 Implants in the U.S.
Seena Magowitz Foundation donates $500,000 for TGen pancreatic cancer research
Major charity golf tournaments in Phoenix and Atlanta help fund successful clinical trials of drug that helps extend patients’ livesContinue reading
UA Spin-Off to Test Cancer-Preventing Drug Combination
From treating cancer to preventing cancer – this is the vision of Tucson-based company Cancer Prevention Pharmaceuticals, co-founded by former UA professor Eugene Gerner.Continue reading
Phase III Colon Cancer Prevention Therapy Trial Now Open for Enrollment
Cancer Prevention Pharmaceuticals, Inc., (CPP) announced today the launch of a Phase III colon cancer prevention trial in collaboration with the National Cancer Institute (NCI) and SWOG, an NCI-supported clinical trials group. The Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) trial is a Phase III trial testing CPP’s prevention therapy product CPP-1X/sul (eflornithine/sulindac) in 1340 colon cancer survivors—each of whom will receive daily treatment for three years to prevent the recurrence of cancer or high-risk polyps.Continue reading